Imperial College London

Professor Hashim Ahmed

Faculty of MedicineDepartment of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Publication Type
Year
to

256 results found

Afaq A, Alahmed S, Chen S-H, Lengana T, Haroon A, Payne H, Ahmed H, Punwani S, Sathekge M, Bomanji Jet al., 2018, Impact of Ga-68-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management, JOURNAL OF NUCLEAR MEDICINE, Vol: 59, Pages: 89-92, ISSN: 0161-5505

JOURNAL ARTICLE

Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, Emberton M, Sculpher MJet al., 2018, Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS), EUROPEAN UROLOGY, Vol: 73, Pages: 23-30, ISSN: 0302-2838

JOURNAL ARTICLE

Faure Walker NA, Norris JM, Shah TT, Yap T, Cathcart P, Moore CM, Ahmed HU, Emberton M, Minhas Set al., 2018, A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review., Urol Oncol, Vol: 36, Pages: 67-76

OBJECTIVES: To systematically review erectile function (EF) outcomes following primary whole gland (WG) and focal ablative therapies for localized prostate cancer to ascertain whether the treatment modality or intended treatment volume affects the time taken to recover baseline EF. METHOD AND MATERIALS: A systematic review was performed according to the preferred reporting items for systematic review and meta-analysis statement. Inclusion criteria were men with localized prostate cancer treated with primary, ablative therapy. Primary outcome was the return to baseline EF measured with objective, validated symptoms scores. Secondary outcome was use of phosphodiesterase inhibitors or erectile aids. Meta-analysis was not performed owing to heterogenous outcome measures. RESULTS: Of 222 articles identified in February 2017, 55 studies which reported EF after ablative therapy were identified but only 17 used validated outcome measures and met inclusion criteria. WG cryotherapy was used in 2 studies, WG high-intensity focused ultrasound (HIFU) in 5, focal cryotherapy in 2, focal HIFU in 3, focal phototherapy or laser therapy in 4, vascular-targeted photodynamic therapy in 3, and irreversible electroporation in 2. WG cryotherapy was associated with a significant decline in EF at 6 months with minimal improvement at 36 months. Baseline IIEF-15 of patients undergoing focal HIFU fell 30 points at 1 month but returned to baseline by 6 months. The remaining focal therapies demonstrated minimal or no effect on EF, but the men in these studies had small foci of disease. The review is limited by lack of randomized studies and heterogenous outcome measures. CONCLUSIONS: Most studies assessing the outcomes of focal therapy on sexual function were not of high quality, used heterogenous outcomes, and had relatively short follow up, highlighting the need for more robustly designed studies using validated patient reported outcome measures  for comparison. However, FT in general res

JOURNAL ARTICLE

Kasivisvanathan V, Ahmed H, Cashman S, Challacombe B, Emberton M, Gao C, Lamb BW, Nambiar A, Pickard R, Shah TT, Smith Det al., 2018, The British Urology Researchers in Surgical Training (BURST) Research Collaborative: an alternative research model for carrying out large scale multi-centre urological studies, BJU INTERNATIONAL, Vol: 121, Pages: 6-9, ISSN: 1464-4096

JOURNAL ARTICLE

Peters M, Kanthabalan A, Shah TT, McCartan N, Moore CM, Arya M, van Zyp JRVDV, Moerland MA, Hindley RG, Emberton M, Ahmed HUet al., 2018, Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, Vol: 36, ISSN: 1078-1439

JOURNAL ARTICLE

Ahmed HU, Bosaily AE-S, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton Met al., 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, LANCET, Vol: 389, Pages: 815-822, ISSN: 0140-6736

JOURNAL ARTICLE

Ahmed HU, Brown LC, Kaplan R, Parker C, Emberton Met al., 2017, Diagnostic accuracy of the PROMIS study Reply, LANCET, Vol: 390, Pages: 362-362, ISSN: 0140-6736

JOURNAL ARTICLE

Bass EJ, Donaldson IA, Freeman A, Jameson C, Punwani S, Moore C, Arya M, Emberton M, Ahmed HUet al., 2017, Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach, PROSTATE CANCER AND PROSTATIC DISEASES, Vol: 20, Pages: 311-317, ISSN: 1365-7852

JOURNAL ARTICLE

Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb Set al., 2017, Complications After Systematic, Random, and Image-guided Prostate Biopsy, EUROPEAN UROLOGY, Vol: 71, Pages: 353-365, ISSN: 0302-2838

JOURNAL ARTICLE

Brizmohun Appayya M, Sidhu HS, Dikaios N, Johnston EW, Simmons LA, Freeman A, Kirkham AP, Ahmed HU, Punwani Set al., 2017, Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI., Br J Radiol

OBJECTIVE: To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multiparametric MRI (mpMRI) studies are classifiable by prostate-specific antigen (PSA), PSA density (PSAD), Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) rescoring and morphological MRI features. METHODS: Men with maximum Likert-score 3/5 within their PZ were retrospectively selected from 330 patients who prospectively underwent prostate mpMRI (3 T) without an endorectal coil, followed by 20-zone transperineal template prostate mapping biopsies +/- focal lesion-targeted biopsy. PSAD was calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and B independently assessed included men with both Likert-assessment and PI-RADS_v2. Both readers then classified mpMRI morphological features in consensus. Men were divided into two groups: significant cancer (≥ Gleason 3 + 4) or insignificant cancer (≤ Gleason 3 + 3)/no cancer. Comparisons between groups were made separately for PSA & PSAD using Mann-Whitney test and morphological descriptors with Fisher's exact test. PI-RADS_v2 and Likert-assessment were descriptively compared and percentage inter-reader agreement calculated. RESULTS: 76 males were eligible for PSA & PSAD analyses, 71 for PI-RADS scoring, and 67 for morphological assessment (excluding significant image artefacts). Unlike PSA (p = 0.915), PSAD was statistically different (p = 0.004) between the significant [median: 0.19 ng ml-2(interquartile range: 0.13-0.29)] and non-significant/no cancer [median: 0.13 ng ml-2(interquartile range: 0.10-0.17)] groups. Presence of mpMRI morphological features was not significantly different between groups. Subjective Likert-assessment discriminated patients with significant cancer better than PI-RADS_v2. Inter-reader percentage agreement was 83% for subjective Likert-assessment and 56% for PI-RADS_v2. CONCLUSION: PSAD may categorize presence of significant cancer in patients with Likert-scored

JOURNAL ARTICLE

Davda R, Prentice M, Sarova A, Nei W, Orczyk C, Arya M, Moore C, Ahmed H, Emberton M, Mitra A, Payne Het al., 2017, Late Toxicity and Patient Reported Outcomes in Patients Treated With Salvage Radiation Following Primary High Intensity Focal Ultrasound for Localized Prostate Cancer, 59th Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO), Publisher: ELSEVIER SCIENCE INC, Pages: E226-E226, ISSN: 0360-3016

CONFERENCE PAPER

Dickinson L, Ahmed HU, Hindley RG, McCartan N, Freeman A, Allen C, Emberton M, Kirkham APet al., 2017, Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, Vol: 35, ISSN: 1078-1439

JOURNAL ARTICLE

Dikaios N, Atkinson D, Tudisca C, Purpura P, Forster M, Ahmed H, Beale T, Emberton M, Punwani Set al., 2017, A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, Vol: 56, Pages: 1-10, ISSN: 0895-6111

JOURNAL ARTICLE

Edison E, Shah TT, Ahmed HU, 2017, Focal Ablation of Early-Stage Prostate Cancer Candidate Selection, Treatment Guidance, and Assessment of Outcome, UROLOGIC CLINICS OF NORTH AMERICA, Vol: 44, Pages: 575-+, ISSN: 0094-0143

JOURNAL ARTICLE

Faria R, Soares M, Spackman E, Ahmed H, Brown L, Rs K, Emberton M, Sculpher Met al., 2017, COST-EFFECTIVENESS OF DIAGNOSIS: FROM TESTS TO LONG-TERM OUTCOMES AND COSTS, Publisher: ELSEVIER SCIENCE INC, Pages: A405-A406, ISSN: 1098-3015

CONFERENCE PAPER

Georgiou PS, Jaros J, Payne H, Allen C, Shah TT, Ahmed HU, Gibson E, Barratt D, Treeby BEet al., 2017, Beam distortion due to gold fiducial markers during salvage high-intensity focused ultrasound in the prostate, MEDICAL PHYSICS, Vol: 44, Pages: 679-693, ISSN: 0094-2405

JOURNAL ARTICLE

Grey A, Scott R, Charman S, van der Meulen J, Frinking P, Acher P, Liyanage S, Madaan S, Constantinescu G, Shah B, Graves CB, Freeman A, Jameson C, Ramachandran N, Emberton M, Arya M, Ahmed HUet al., 2017, The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer., Contemp Clin Trials, Vol: 66, Pages: 86-92

OBJECTIVE: To compare the proportion of clinically significant prostate cancers (PCa) found in lesions detected by multiparametric MRI (mpMRI) with that found in lesions detected by multiparametric ultrasound (mpUSS), in men at risk. PATIENTS AND METHODS: CADMUS (Cancer Detection by Multiparametric Ultrasound of the prostate) is a prospective, multi-centre paired cohort diagnostic utility study with built-in randomisation of order of biopsies. The trial is registered ISRCTN38541912. All patients will undergo the index test under evaluation (mpUSS±biopsies), as well as the standard test (mpMRI±biopsies). Eligible men will be those at risk of harbouring prostate cancer usually recommended for prostate biopsy, either for the first time or as a repeat, who have not had any prior treatment for prostate cancer. Men in need of repeat biopsy will include those with prior negative results but ongoing suspicion, and those with an existing prostate cancer diagnosis but a need for accurate risk stratification. Both scans will be reported blind to the results of the other and the order in which the targeted biopsies derived from the two different imaging modalities are taken will be randomised. Comparison will be drawn between biopsy results of lesions detected by mpUSS with those lesions detected by mpMRI. Agreement over position between the two imaging modalities will be studied. DISCUSSION: CADMUS will provide level one evidence on the performance of mpUSS derived targeted biopsies in the identification of clinically significant prostate cancer in comparison to mpMRI targeted biopsies. Recruitment is underway and expected to complete in 2018.

JOURNAL ARTICLE

Grey ADR, Ahmed HU, 2017, Re: Limitations of Elastography Based Prostate Biopsy, JOURNAL OF UROLOGY, Vol: 197, Pages: 263-264, ISSN: 0022-5347

JOURNAL ARTICLE

Hindley RG, Mistry K, Ahmed HU, 2017, The PROMIS of a New Diagnostic Pathway for Men with Suspected Prostate Cancer., Clin Oncol (R Coll Radiol), Vol: 29, Pages: 397-400

JOURNAL ARTICLE

Hu Y, Kasivisvanathan V, Simmons LAM, Clarkson MJ, Thompson SA, Shah TT, Ahmed HU, Punwani S, Hawkes DJ, Emberton M, Moore CM, Barratt DCet al., 2017, Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy, IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, Vol: 64, Pages: 946-958, ISSN: 0018-9294

JOURNAL ARTICLE

Kanthabalan A, Peters M, Van Vulpen M, McCartan N, Hindley RG, Emara A, Moore CM, Arya M, Emberton M, Ahmed HUet al., 2017, Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer, BJU INTERNATIONAL, Vol: 120, Pages: 246-256, ISSN: 1464-4096

JOURNAL ARTICLE

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton Cet al., 2017, Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters, ANNALS OF ONCOLOGY, Vol: 28, Pages: 2472-2480, ISSN: 0923-7534

JOURNAL ARTICLE

MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N, Lam T, COMPACTERS Study Groupet al., 2017, A core outcome set for localised prostate cancer effectiveness trials., BJU Int, Vol: 120, Pages: E64-E79

OBJECTIVE: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which offers the optimal therapeutic ratio; which is confounded by inconsistencies in the selection, definition, measurement and reporting of outcomes in clinical trials. PATIENTS, SUBJECTS AND METHODS: A list of 79 outcomes was derived from a systematic review of published localised prostate cancer effectiveness studies and semi-structured interviews with 15 patients with prostate cancer patients. A two-stage consensus process involving 118 patients and 56 international healthcare professionals (HCPs; cancer specialist nurses, urological surgeons and oncologists) was undertaken, consisting of a three-round Delphi survey followed by a face-to-face consensus panel meeting of 13 HCPs and eight patients. RESULTS: The final COS included 19 outcomes. In all, 12 apply to all interventions: death from prostate cancer, death from any cause, local disease recurrence, distant disease recurrence/metastases, disease progression, need for salvage therapy, overall quality of life, stress urinary incontinence, urinary function, bowel function, faecal incontinence, and sexual function. Seven were intervention-specific: perioperative deaths (surgery), positive surgical margin (surgery), thromboembolic disease (surgery), bothersome or symptomatic urethral or anastomotic stricture (surgery), need for curative treatment (active surveillance), treatment failure (ablative therapy), and side-effects of hormonal therapy (hormone therapy). The UK-centric participants may limit the generalisability to other countries, but trialists should reason why the COS would not be applicable. The default position should not be that a COS developed in one country will automatically not be applicable elsewhere. CONCLUSION: We have established a COS for trials of effectiveness in localised prostate

JOURNAL ARTICLE

Miah S, Ahmed HU, 2017, The death of ink: the value of typing skills as an addition to the medical school curriculum, ADVANCES IN MEDICAL EDUCATION AND PRACTICE, Vol: 8, Pages: 701-702, ISSN: 1179-7258

JOURNAL ARTICLE

Moore CM, Robertson NL, Jichi F, Damola A, Ambler G, Giganti F, Ridout AJ, Bott SRJ, Winkler M, Ahmed HU, Arya M, Mitra AV, McCartan N, Freeman A, Jameson C, Castro R, Gambarota G, Whitcher BJ, Allen C, Kirkham A, Emberton Met al., 2017, The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial, JOURNAL OF UROLOGY, Vol: 197, Pages: 1006-1013, ISSN: 0022-5347

JOURNAL ARTICLE

Segaran SV, Emara AM, Mahesan T, Silverman J, Ahmed HU, Bott SRJ, Hindley RGet al., 2017, The ability of free to total prostate-specific antigen and prostate-specific antigen density to detect clinically significant prostate cancer in men undergoing transperineal template biopsy, JOURNAL OF CLINICAL UROLOGY, Vol: 10, Pages: 529-534, ISSN: 2051-4158

JOURNAL ARTICLE

Shah TT, To WKL, Ahmed HU, 2017, Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways, EXPERT REVIEW OF ANTICANCER THERAPY, Vol: 17, Pages: 1159-1168, ISSN: 1473-7140

JOURNAL ARTICLE

Sidhu HS, Benigno S, Ganeshan B, Dikaios N, Johnston EW, Allen C, Kirkham A, Groves AM, Ahmed HU, Emberton M, Taylor SA, Halligan S, Punwani Set al., 2017, "Textural analysis of multiparametric MRI detects transition zone prostate cancer", EUROPEAN RADIOLOGY, Vol: 27, Pages: 2348-2358, ISSN: 0938-7994

JOURNAL ARTICLE

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00936994&limit=30&person=true